Last reviewed · How we verify
Voclosporin Low Dose
At a glance
| Generic name | Voclosporin Low Dose |
|---|---|
| Also known as | ISA247 |
| Sponsor | Aurinia Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) (PHASE2)
- Study of ISA247 (Voclosporin) in De Novo Renal Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voclosporin Low Dose CI brief — competitive landscape report
- Voclosporin Low Dose updates RSS · CI watch RSS
- Aurinia Pharmaceuticals Inc. portfolio CI